Experts and Doctors on prostatic neoplasms in New York, United States


Locale: New York, United States
Topic: prostatic neoplasms

Top Publications

  1. Cohen G, Amols H, Zaider M. An independent dose-to-point calculation program for the verification of high-dose-rate brachytherapy treatment planning. Int J Radiat Oncol Biol Phys. 2000;48:1251-8 pubmed
    ..For more general applications, the calculated and planned doses are typically within 3% at the prescription isodose line. The Manchester-based dwell time calculation is within 10% of the planned time. ..
  2. Ye F, Xui L, Yi J, Zhang W, Zhang D. Anticancer activity of Scutellaria baicalensis and its potential mechanism. J Altern Complement Med. 2002;8:567-72 pubmed
    ..This study supports the notion of using Scutellaria baicalensis as a novel anticancer agent to treat various cancers. ..
  3. Li Y, Raffo A, Drew L, Mao Y, Tran A, Petrylak D, et al. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143. Cancer Res. 2003;63:1527-33 pubmed
    ..This model may be a useful tool for dissecting the specific interactions between wild-type p53 and the Fas signal transduction pathway in human cancer cells. ..
  4. Bianco F, Riedel E, Begg C, Kattan M, Scardino P. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol. 2005;173:2099-103 pubmed
  5. Pillarsetty N, Punzalan B, Larson S. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer. J Nucl Med. 2009;50:1709-14 pubmed publisher
    ..94 and 2.06, respectively. The data presented here indicate that (18)F-FPA accumulates in prostate cancers with high tumor-to-background ratios. (18)F-FPA has potential for use in the clinical diagnosis of prostate cancer in humans. ..
  6. Vickers A, Savage C, Bianco F, Mulhall J, Sandhu J, Guillonneau B, et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol. 2011;59:317-22 pubmed publisher
    ..Functional preservation does not appear to come at the expense of cancer control; rather, both are related to surgical quality. ..
  7. Rundle A, Jankowski M, Kryvenko O, Tang D, Rybicki B. Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol Biomarkers Prev. 2013;22:898-904 pubmed publisher
    ..48). Obesity is associated with the presence of PIN in benign specimens and with future prostate cancer risk after an initial benign finding. Obesity may be a factor to consider when planning clinical follow-up after a benign biopsy. ..
  8. Kobayashi T, Wang J, Al Ahmadie H, Abate Shen C. ARF regulates the stability of p16 protein via REG?-dependent proteasome degradation. Mol Cancer Res. 2013;11:828-33 pubmed publisher
    ..The ability of ARF to control p16 stability may influence cell-cycle function. The ability of ARF to control p16 stability may influence cell cycle function. Visual Overview: ..
  9. Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long H, et al. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016;7:10979 pubmed publisher
    ..Our findings showcase the power of integrating functional annotation with genetic data to understand the genetic basis of PrCa. ..

More Information

Publications410 found, 100 shown here

  1. Pinto J, Suffoletto B, Berzin T, Qiao C, Lin S, Tong W, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445-51 pubmed
    ..Those developing future therapeutic strategies in the treatment of prostate cancer that utilize folate antagonists need to consider this mechanism of resistance. ..
  2. Bjartell A, Al Ahmadie H, Serio A, Eastham J, Eggener S, Fine S, et al. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007;13:4130-8 pubmed
    ..However, addition of the markers does not importantly improve the performance of existing predictive models. Further research should aim to elucidate the functions of CRISP-3 and MSP in prostate cancer cells. ..
  3. Lu M, Xia L, Hua H, Jing Y. Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res. 2008;68:1180-6 pubmed publisher
    ..These results suggest that AKBA induces apoptosis in prostate cancer cells through a DR5-mediated pathway, which probably involves the induced expression of CHOP. ..
  4. Weinstein B. Relevance of the concept of oncogene addiction to hormonal carcinogenesis and molecular targeting in cancer prevention and therapy. Adv Exp Med Biol. 2008;617:3-13 pubmed publisher
  5. Xu B, Chevarie Davis M, Chevalier S, Scarlata E, Zeizafoun N, Dragomir A, et al. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature. Hum Pathol. 2014;45:488-97 pubmed publisher
    ..Our results, as well as an extensive review of the related literature showing conflicting findings, seem to indicate that ERG immunopositivity cannot be considered as an important prognostic factor in prostate cancer. ..
  6. Gil Z, Kelly K, Brader P, Shah J, Fong Y, Wong R. Utility of a herpes oncolytic virus for the detection of neural invasion by cancer. Neoplasia. 2008;10:347-53 pubmed
    ..This method may improve the diagnosis and treatment of patients with neurotrophic cancers by reducing injury to normal nerves and facilitating identification of infiltrated nerves requiring resection. ..
  7. Muller A, Parker M, Waters B, Flanigan R, Mulhall J. Penile rehabilitation following radical prostatectomy: predicting success. J Sex Med. 2009;6:2806-12 pubmed publisher
    ..Predictors of successful outcome included NS surgery, early post-RP presentation, young age, and absence of vascular comorbidities. ..
  8. von Bodman C, Godoy G, Chade D, Cronin A, Tafe L, Fine S, et al. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol. 2010;184:143-8 pubmed publisher
    ..A large subset of those patients had a favorable prognosis. Full bilateral pelvic lymph node dissection should be done in patients with intermediate and high risk cancer to identify those likely to benefit from metastatic node removal. ..
  9. Zhang P, Mah D, Happersett L, Cox B, Hunt M, Mageras G. Determination of action thresholds for electromagnetic tracking system-guided hypofractionated prostate radiotherapy using volumetric modulated arc therapy. Med Phys. 2011;38:4001-8 pubmed
    ..Such methods can provide improved sensitivity and specificity compared to conventional methods, which assume directionally symmetric action thresholds. ..
  10. Barbieri C, Demichelis F, Rubin M. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology. 2012;60:187-98 pubmed publisher
  11. Zammarchi F, Boutsalis G, Cartegni L. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer. PLoS ONE. 2013;8:e49721 pubmed publisher
    ..Usage of this ATG can be preferentially down-regulated by directed antisense-based compounds, possibly representing the basis of a targeted approach that distinguishes between tumor-associated and normal ERG. ..
  12. Zelefsky M, Yamada Y, Marion C, Sim S, Cohen G, Ben Porat L, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:956-63 pubmed
    ..These changes have led to a more favorable acute toxicity profile for patients treated with this technique without compromising biochemical control. ..
  13. Narayanan B, Reddy B, Bosland M, Nargi D, Horton L, Randolph C, et al. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Clin Cancer Res. 2007;13:5965-73 pubmed
    ..In this study, we show for the first time that the combination of celecoxib with exisulind at low doses could prevent prostate carcinogenesis by altering key molecular events. ..
  14. Cho H, Ackerstaff E, Carlin S, Lupu M, Wang Y, Rizwan A, et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia. 2009;11:247-59, 2p following 259 pubmed
  15. Crawford E, Stone N, Yu E, Koo P, Freedland S, Slovin S, et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014;83:664-9 pubmed publisher
    ..The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer. ..
  16. Alme A, Karir B, Faltas B, Drake C. Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol. 2016;34:171-81 pubmed publisher
    ..There are several ongoing and planned trials in genitourinary malignancies of single-agent inhibitors, as well as combinations targeting multiple checkpoints or adding other types of therapies to checkpoint blockade. ..
  17. Yu Y. Multiobjective decision theory for computational optimization in radiation therapy. Med Phys. 1997;24:1445-54 pubmed
    ..Overall, the present formalism provides a realistic alternative to complete utility assessment or human-guided exploration of the efficient solution set. ..
  18. Melamed J, Datta M, Becich M, Orenstein J, Dhir R, Silver S, et al. The cooperative prostate cancer tissue resource: a specimen and data resource for cancer researchers. Clin Cancer Res. 2004;10:4614-21 pubmed
    ..Interested investigators are encouraged to apply for use of this material ( ..
  19. Agalliu I, Gern R, Leanza S, Burk R. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res. 2009;15:1112-20 pubmed publisher
    ..These findings should be carefully considered in genetic counseling and/or evaluating therapeutic options. ..
  20. Hu L, Ibrahim S, Liu C, Skaar J, Pagano M, Karpatkin S. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res. 2009;69:3374-81 pubmed publisher
    ..04). Repetitive hirudin, a specific potent antithrombin, decreased tumor volume 13- to 24-fold (P < 0.04). Thus, thrombin stimulates tumor cell growth in vivo by down-regulation of p27(Kip1). ..
  21. Wang X, Kruithof de Julio M, Economides K, Walker D, Yu H, Halili M, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009;461:495-500 pubmed publisher
    ..These observations indicate that CARNs represent a new luminal stem cell population that is an efficient target for oncogenic transformation in prostate cancer. ..
  22. Roth A, Nelson C, Rosenfeld B, Scher H, Slovin S, Morris M, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010;116:5102-10 pubmed publisher
    ..There were no serious adverse events. Methylphenidate is effective in treating fatigue in men with prostate cancer; however, oncologists need to monitor for possible pulse and blood pressure elevations. ..
  23. Shariat S, Chromecki T, Hoefer J, Barbieri C, Scherr D, Karakiewicz P, et al. Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol. 2011;186:2107-14 pubmed publisher
    ..Data suggest that soluble gp130 has a role in prostate cancer invasion in an interleukin-6 dependent and independent manner. ..
  24. Dennis E, Jia X, Mezheritskiy I, Stephenson R, Schoder H, Fox J, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519-24 pubmed publisher
    ..These data furnish early evidence that on-treatment changes in BSI are a response indicator and support further exploration of bone scintigraphy as an imaging biomarker in CRMPC. ..
  25. Barbieri C, Baca S, Lawrence M, Demichelis F, Blattner M, Theurillat J, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685-9 pubmed publisher
    ..Prostate cancers with mutant SPOP lacked ETS family gene rearrangements and showed a distinct pattern of genomic alterations. Thus, SPOP mutations may define a new molecular subtype of prostate cancer. ..
  26. Ligr M, Li Y, Logan S, Taneja S, Melamed J, Lepor H, et al. Mifepristone inhibits GR? coupled prostate cancer cell proliferation. J Urol. 2012;188:981-8 pubmed publisher
    ..Results suggest that patients with a primary tumor that expresses GR? and ARA70? may benefit from mifepristone. ..
  27. Swisher McClure S, Yin L, Rosen M, Batra S, Berman A, Both S, et al. Prospective MRI-based imaging study to assess feasibility of proton therapy for post-prostatectomy radiation. Acta Oncol. 2016;55:828-33 pubmed publisher
    ..Patient alignment using bony anatomy as well as the ERB minimizes displacement of the CTV, and reduces variation in target dose coverage particularly for PBS proton therapy. ..
  28. Rickman D, Beltran H, Demichelis F, Rubin M. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017;23:1-10 pubmed publisher
    ..We discuss the shared genomic alterations of these tumors independently of their site of origin, and we explore potential therapeutic strategies on the basis of recent biological findings. ..
  29. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan W. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol. 1992;6:2123-8 pubmed
  30. Rotariu P, Yohannes P, Alexianu M, Rosner D, Lee B, Lucan M, et al. Management of malignant extrinsic compression of the ureter by simultaneous placement of two ipsilateral ureteral stents. J Endourol. 2001;15:979-83 pubmed
    ..2 mg/dL to 1.48 mg/dL in the five patients tested. Simultaneous placement of two double-J ureteral stents for the management of ureteral obstruction secondary to a malignancy is a safe and effective technique. ..
  31. Peng Y, Chiriboga L, Yee H, Pei Z, Wang Z, Lee P. Androgen receptor coactivator ARA70alpha and ARA70beta isoform-specific antibodies: new tools for studies of expression and immunohistochemical localization. Appl Immunohistochem Mol Morphol. 2008;16:7-12 pubmed
    ..ARA70beta localized to the cytosol, whereas ARA70alpha was found in the nucleus, supporting the notion of their dissimilar functions. ..
  32. Lee D, Cheetham P, Badani K. Predictors of early urinary continence after robotic prostatectomy. Can J Urol. 2010;17:5200-5 pubmed
    ..Patient age remains the strongest predictor of early return of continence in a multivariate model. These factors should be used in counseling prior to surgery to meet realistic patient expectations. ..
  33. Beltran H, Beer T, Carducci M, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60:279-90 pubmed publisher
    ..With our improved understanding of tumor biology and the incorporation of new prognostic and molecular biomarkers into clinical trials, we are making progress in the management of patients with CRPC. ..
  34. Mita P, Savas J, Djouder N, Yates J, Ha S, Ruoff R, et al. Regulation of androgen receptor-mediated transcription by RPB5 binding protein URI/RMP. Mol Cell Biol. 2011;31:3639-52 pubmed publisher
    ..1 promoter. While Art-27 can bind AR directly, URI is bound to chromatin prior to hormone-dependent recruitment of AR, suggesting a role for URI in modulating AR recruitment to target genes. ..
  35. Basch E, Oliver T, Vickers A, Thompson I, Kantoff P, Parnes H, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012;30:3020-5 pubmed publisher
    ..Adverse events associated with prostate biopsy are low for the majority of men; however, several population-based studies have shown increasing rates of infectious complications after prostate biopsy, which is a concern. ..
  36. Floc h N, Kinkade C, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A, et al. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res. 2012;72:4483-93 pubmed publisher
    ..Our findings suggest that dual targeting of the Akt and mTOR signaling pathways using MK-2206 and ridaforolimus (MK-8669) may be effective for treatment of CRPC, particularly for patients with deregulated Rb pathway activity. ..
  37. Snyder A, Tepper J, Slovin S. Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?. Semin Oncol. 2013;40:347-60 pubmed publisher
    ..Where we are and where we will likely go are the topics to be discussed in this review. ..
  38. Miller M, Kostakoglu L, Pryma D, Yu J, Chau A, Perlman E, et al. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using 18F-Fluciclovine PET/CT. J Nucl Med. 2017;58:1596-1602 pubmed publisher
  39. Anastasiadis A, Ghafar M, Salomon L, Vacherot F, Benedit P, Chen M, et al. Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha). J Cancer Res Clin Oncol. 2002;128:358-62 pubmed
    ..We believe that these mutations might enable expression of this protein under inappropriate conditions and contribute to the development of therapeutic resistance by the cancer cells. This hypothesis is currently being tested. ..
  40. Shen R, Milowsky M, Ozaki N, Navarro D, Sumitomo M, Xu Y, et al. Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase. Anticancer Res. 2002;22:2533-8 pubmed
    ..Furthermore, this work demonstrates the ability of mass spectrometry to identify proteins interacting with NEP and potentially other cell-surface peptidases. ..
  41. Narla G, Difeo A, Yao S, Banno A, Hod E, Reeves H, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 2005;65:5761-8 pubmed
    ..Together, these findings begin to highlight a dynamic and functional antagonism between wtKLF6 and its splice variant KLF6 SV1 in tumor growth and dissemination. ..
  42. Sala E, Akin O, Moskowitz C, Eisenberg H, Kuroiwa K, Ishill N, et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology. 2006;238:929-37 pubmed
    ..Endorectal MR imaging is accurate in demonstrating SVI prior to radical prostatectomy, and recognition of the most predictive features may facilitate the use of this modality. ..
  43. Lee D, Ritch C, Desai M, Benson M, McKiernan J. The interaction of body mass index and race in predicting biochemical failure after radical prostatectomy. BJU Int. 2011;107:1741-7 pubmed publisher
    ..These findings suggest that elevated BMI does not affect the BCF rates of black men more than in other races, and that other factors may influence the racial variability in disease-free survival and BCF risk. ..
  44. Rathkopf D, Liu G, Carducci M, Eisenberger M, Anand A, Morris M, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res. 2011;17:880-7 pubmed publisher
  45. Vijai J, Kirchhoff T, Gallagher D, Hamel N, Guha S, Darvasi A, et al. Genetic architecture of prostate cancer in the Ashkenazi Jewish population. Br J Cancer. 2011;105:864-9 pubmed publisher
    ..We see no convincing evidence that the genetic architecture of prostate cancer in the AJ population is substantively different from that observed in other populations of European ancestry. ..
  46. Tang D, Kryvenko O, Wang Y, Jankowski M, Trudeau S, Rundle A, et al. Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans. Carcinogenesis. 2013;34:113-20 pubmed publisher
  47. Atkinson T, Halabi S, Bennett A, Rogak L, Sit L, Li Y, et al. Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. Pain Med. 2012;13:1417-24 pubmed publisher
  48. Mistry S, Oh W. New paradigms in microtubule-mediated endocrine signaling in prostate cancer. Mol Cancer Ther. 2013;12:555-66 pubmed publisher
    ..This may have important implications in designing mechanism-based and targeted-therapeutic strategies for prostate cancer. ..
  49. Haghighi M, Shah S, Taneja S, Rosenkrantz A. Prostate cancer: diffusion-weighted imaging versus dynamic-contrast enhanced imaging for tumor localization-a meta-analysis. J Comput Assist Tomogr. 2013;37:980-8 pubmed publisher
    ..Larger studies with uniform methodology are warranted to further understand relative merits of the 2 techniques. ..
  50. Vickers A. What are the implications of the surgical learning curve?. Eur Urol. 2014;65:532-3 pubmed publisher
  51. Imnadze M, Sjoberg D, Vickers A. Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes. Eur Urol. 2016;69:143-8 pubmed publisher
    ..The risk of biochemical recurrence associated with adverse pathologic findings at prostatectomy is reduced by approximately 50% in men with clinically low-risk prostate cancer. ..
  52. Zhang X, Lee C, Ng P, Rubin M, Shabsigh A, Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate. 2000;43:278-85 pubmed
  53. Yao D, Trabulsi E, Kostakoglu L, Vallabhajosula S, Joyce M, Nanus D, et al. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol. 2002;20:211-8 pubmed
    ..Radioimmunoscintigraphy with this immunoconjugate has demonstrated excellent tumor targeting of prostate cancer sites not only in soft tissue but also in bone. ..
  54. Wang L, Lin H, Hu Y, Xie S, Yang L, Chang C. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem. 2004;279:32444-52 pubmed
    ..Together, our data demonstrated that GSK3 beta may function as a repressor to suppress AR-mediated transactivation and cell growth, which may provide a new strategy to modulate the AR-mediated prostate cancer growth. ..
  55. Salm S, Burger P, Coetzee S, Goto K, Moscatelli D, Wilson E. TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol. 2005;170:81-90 pubmed
    ..In addition to highlighting the regulatory role of androgens and TGF-beta, these findings may have important implications for the deregulation of the stem cell compartment in the etiology of proliferative prostatic diseases. ..
  56. Slova D, Lepor H. The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. J Urol. 2007;178:2397-400; discussion 2400-1 pubmed
    ..This beneficial effect of radical prostatectomy on the natural history of lower urinary tract symptoms should be considered when weighing the risks and benefit of the treatment option for localized prostate cancer. ..
  57. Liu X, Gomez Pinillos A, Liu X, Johnson E, Ferrari A. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. Prostate. 2010;70:179-89 pubmed publisher
    ..Biologically, LBH589 reverses the resistance of AI-cells to bicalutamide and to apoptosis. The combination may restore the hormonal response of castration-resistant PC patients. ..
  58. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res. 2010;16:3232-9 pubmed publisher
    ..A panel of four kallikreins can help predict the result of initial biopsy in previously screened men with elevated PSA. Use of a statistical model based on the panel would substantially decrease rates of unnecessary biopsy. ..
  59. Yap K, Li S, Muñoz Cabello A, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38:662-74 pubmed publisher
    ..Our study suggests a mechanism by which noncoding RNA participates directly in epigenetic transcriptional repression. ..
  60. Cheetham P, Katz A. Diet and prostate cancer - a holistic approach to management. Arch Esp Urol. 2011;64:720-34 pubmed
    ..Most nutritional chemoprevention agents also have the added benefit of being beneficial for the cardiovascular system, bone health and for the prevention of other cancers. ..
  61. Kashyap V, Ahmad S, Nilsson E, Helczynski L, Kenna S, Persson J, et al. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol Oncol. 2013;7:555-66 pubmed publisher
    ..New therapies targeting LSD1 activity should be useful in the treatment of hormone dependent and independent prostate cancer. ..
  62. MENG X, Rosenkrantz A, Mendhiratta N, Fenstermaker M, Huang R, Wysock J, et al. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. Eur Urol. 2016;69:512-7 pubmed publisher
    ..We found that MRI-targeted biopsy detected more high-grade cancers than systematic biopsy, and that MRI performed before biopsy can predict the risk of high-grade cancer. ..
  63. Zelefsky M, Poon B, Eastham J, Vickers A, Pei X, Scardino P. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol. 2016;118:85-91 pubmed publisher
    ..Treatment selection should include patient preferences and balance predicted disease-free survival over a projected time vs potential impairment of QoL important for the patient. ..
  64. Zahalka A, Arnal Estapé A, Maryanovich M, Nakahara F, Cruz C, Finley L, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science. 2017;358:321-326 pubmed publisher
    ..This cross-talk between nerves and endothelial metabolism could potentially be targeted as an anticancer therapy. ..
  65. Zang X, Thompson R, Al Ahmadie H, Serio A, Reuter V, Eastham J, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104:19458-63 pubmed
    ..Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer. ..
  66. Powell C, Fair W, Heston W. Differential expression of protein kinase C isozyme messenger RNAs in dunning R-3327 rat prostatic tumors. Cell Growth Differ. 1994;5:143-9 pubmed
    ..We have cloned and report the sequence of the novel portion of the alternatively spliced form of PKC zeta RNA, which is polyadenylated and present in cytoplasm. ..
  67. Xiong J, Fan S, Meng Q, Schramm L, Wang C, Bouzahza B, et al. BRCA1 inhibition of telomerase activity in cultured cells. Mol Cell Biol. 2003;23:8668-90 pubmed
    ..Finally, endogenous BRCA1 and c-Myc were detected on transfected mouse and human TERT promoter segments in vivo. We postulate that inhibition of telomerase may contribute to the BRCA1 tumor suppressor activity. ..
  68. Gong J, Zhu J, Goodman O, Pestell R, Schlegel P, Nanus D, et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene. 2006;25:2011-21 pubmed
    ..Together these results demonstrate that bombesin, via Src and PKCdelta signaling pathways, activates p300 HAT activity which leads to enhanced acetylation of AR resulting in increased expression of AR-regulated genes. ..
  69. Godoy G, Tareen B, Lepor H. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. BJU Int. 2009;104:1610-4 pubmed publisher
    ..The risk of BCR was dependent on the site and not the number of PSMs. Adjuvant therapy should be considered in cases with anterior and basilar PSMs due to the very high risk of BCR. ..
  70. Touma S, Perner S, Rubin M, Nanus D, Gudas L. Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem Pharmacol. 2009;78:1127-38 pubmed publisher
    ..Our data indicate that this reduction in ALDH1A2 protein is an early event in human prostate cancer. ..
  71. Lee D, Cheetham P, Badani K. Penile rehabilitation protocol after robot-assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency. BJU Int. 2010;105:382-8 pubmed publisher
    ..With longer-term follow-up, we need to further define the factors that improve overall recovery of sexual function after RAP. ..
  72. Green D, Karpatkin S. Role of thrombin as a tumor growth factor. Cell Cycle. 2010;9:656-61 pubmed
  73. Park K, Tomlins S, Mudaliar K, Chiu Y, Esgueva R, Mehra R, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590-8 pubmed
    ..Given the ease of performing IHC versus FISH, ERG protein expression may be useful for molecularly subtyping prostate cancer based on ERG rearrangement status and suggests clinical utility in prostate needle biopsy evaluation. ..
  74. Scher H, Jia X, Chi K, de Wit R, Berry W, Albers P, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29:2191-8 pubmed publisher
    ..This difference might be due to either weekly docetaxel dosing, which, in a prior study, showed a trend toward inferior survival compared with an every-3-weeks regimen, or DN-101 therapy. ..
  75. Fine S. Variants and unusual patterns of prostate cancer: clinicopathologic and differential diagnostic considerations. Adv Anat Pathol. 2012;19:204-16 pubmed publisher
    ..This article details a number of variants, with emphasis on diagnostic criteria, differential diagnoses, and clinical significance. ..
  76. Wassberg C, Akin O, Vargas H, Shukla Dave A, Zhang J, Hricak H. The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol. 2012;199:360-6 pubmed publisher
    ..39) to moderate (? = 0.58). CE-MRI increased interobserver agreement and offered incremental value to T2-weighted MRI in the detection of locally recurrent prostate cancer for the relatively inexperienced reader. ..
  77. Vickers A, Ulmert D, Sjoberg D, Bennette C, Bjork T, Gerdtsson A, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023 pubmed publisher
    ..Given existing data on the risk of death by PSA concentration at age 60, these results suggest that three lifetime PSA tests (mid to late 40s, early 50s, and 60) are probably sufficient for at least half of men. ..
  78. Morris M, Autio K, Basch E, Danila D, Larson S, Scher H. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?. Semin Oncol. 2013;40:375-92 pubmed publisher
    ..In this review, we critically assess each of these classes of novel biomarkers--imaging, CTC, and PROs--in regard to the quality of data supporting their use to monitor clinical outcomes in advanced prostate cancer. ..
  79. Rosenkrantz A, Taneja S. Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. AJR Am J Roentgenol. 2014;202:109-20 pubmed publisher
    ..Strategies for addressing these challenges are suggested...
  80. Braun K, Sjoberg D, Vickers A, Lilja H, Bjartell A. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol. 2016;69:505-11 pubmed publisher
    ..The model helps reduce unnecessary biopsies without missing an undue number of high-grade cancers. ..
  81. Su Z, Lin J, Shen R, Fisher P, Goldstein N, Fisher P. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc Natl Acad Sci U S A. 1996;93:7252-7 pubmed
    ..The approaches described in this paper, SEM combined with expression cloning, should prove of wide utility for developing immunological reagents specific for and identifying genes relevant to human cancer. ..
  82. Rabbani F, Vora K, Yunis L, Eastham J, Guillonneau B, Scardino P, et al. Biochemical recurrence rate in patients with positive surgical margins at radical prostatectomy with further negative resected tissue. BJU Int. 2009;104:605-10 pubmed publisher
    ..While the few patients with PSMs and further negative resected tissue limited the statistical analysis, it would appear that in these patients the disease behaves as in those with negative margins. ..
  83. Cao J, Kozarekar P, Pavlaki M, Chiarelli C, Bahou W, Zucker S. Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration. J Biol Chem. 2004;279:14129-39 pubmed
    ..These data demonstrated that each domain of MT1-MMP plays a distinct role in substrate degradation and cell migration. ..
  84. Nwachukwu J, Mita P, Ruoff R, Ha S, Wang Q, Huang S, et al. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Cancer Res. 2009;69:3140-7 pubmed publisher
    ..Our studies show that reduction of ART-27 protein levels in prostate cancer may facilitate antiandrogen-resistant disease. ..
  85. Evans M, Smith Jones P, Wongvipat J, Navarro V, Kim S, Bander N, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578-82 pubmed publisher
  86. Danila D, Fleisher M, Scher H. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011;17:3903-12 pubmed publisher
    ..Prospective studies, designed around the biomarker itself and the specific clinical context for which it is applied, are needed to further assess the role of these and novel markers in clinical practice. ..
  87. Oh W, Galsky M, Stadler W, Srinivas S, Chu F, Bubley G, et al. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011;78:626-30 pubmed publisher
    ..Therefore, additional evaluation in CRPC patients is not warranted. IPI-504 is being investigated at less-intensive doses and schedules in other tumor types. ..
  88. Galsky M, Small A, Tsao C, Oh W. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA Cancer J Clin. 2012;62:299-308 pubmed publisher
  89. Zaider T, Manne S, Nelson C, Mulhall J, Kissane D. Loss of masculine identity, marital affection, and sexual bother in men with localized prostate cancer. J Sex Med. 2012;9:2724-32 pubmed publisher
    ..Furthermore, its impact on adjustment in survivorship may rely on the quality of their intimate relationships. ..
  90. Nastiuk K, Mansukhani M, Terry M, Kularatne P, Rubin M, Melamed J, et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate. 1999;40:172-7 pubmed
    ..This suggests that unlike cases of breast and ovarian cancers, mutations in BRCA1 or BRCA2 do not significantly predispose men to prostate cancer. ..
  91. Huang Y, Li J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost. 2001;86:1094-8 pubmed
    ..This could help explain how thrombin promotes angiogenesis. ..
  92. Ghafar M, Golliday E, Bingham J, Mansukhani M, Anastasiadis A, Katz A. Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: a case report. J Altern Complement Med. 2002;8:493-7 pubmed